In response to: Parodi MB, Iacono P, Zucchiatti I, et al. Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab

Abstract

In response to the article by Parodi et al. about choroidal neovascularization (CNV) associated with Multiple Evanescent White Dot Syndrome (MEWDS) treated with intravitreal Ranibizumab. This article highlights the efficacy of intravitreal Ranibizumab in the treatment of CNV associated with MEWDS. In our experience, CNV is mostly associated with MEWDS in cases of a wider inflammatory spectrum such as overlapping syndrome with multifocal choroiditis (MFC) or punctuate inner choroidopathy (PIC). The whole pattern of the case presented in the article is compatible with the diagnosis of PIC, meaning that this case described an overlapping between MEWDS and PIC diagnoses. Although the authors wrote that CNV is secondary to MEWDS, another possible hypothesis is that CNV is secondary to PIC. Thus, MEWDS could be secondary to PIC and/or CNV.

This article refers to:

Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab

This article is referred to by:

Regarding comments by Mathis T and Kodjikian L on “Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab”

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.